Tirzepatide co-administration causes lithium toxicity requiring hemodialysis in stable Bipolar I patient

Patients with Bipolar I Disorder often require long-term lithium therapy, a mood stabilizer with a narrow therapeutic index, meaning small changes in dosage or clearance can lead to toxicity. Concurrently, metabolic comorbidities like obesity and type 2 diabetes are prevalent in this population, leading to increased use of novel agents like glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP) agonists. While GLP-1 RAs offer significant metabolic benefits, their potential for drug-drug interactions, particularly with renally cleared drugs like lithium, is a critical safety concern that warrants careful investigation.

This report details a case of severe lithium toxicity in a patient with previously stable Bipolar I Disorder following the initiation of tirzepatide. The patient was on a stable lithium regimen prior to starting the GLP-1/GIP receptor agonist. The clinical course, including the onset of toxicity symptoms, changes in lithium plasma levels, and the subsequent medical interventions, was documented. The primary focus was on identifying the temporal relationship between tirzepatide administration and the development of lithium toxicity, leading to the need for advanced medical care.

Following the introduction of tirzepatide, the patient developed symptoms consistent with acute lithium toxicity. This adverse event was severe enough to necessitate hemodialysis to remove excess lithium from the bloodstream. This outcome strongly suggests a significant drug-drug interaction between tirzepatide and lithium, leading to elevated lithium concentrations beyond the therapeutic range. The precise mechanism, whether through altered renal clearance, gastrointestinal effects, or other pharmacokinetic changes induced by tirzepatide, remains to be fully elucidated but the clinical consequence was undeniable.

The patient's lithium toxicity was so severe it required hemodialysis, highlighting a critical safety concern for co-administration.